Novartis's Tislelizumab Takes First Step On US Approval Path
Aiming To Reach Crowded Checkpoint Inhibitor Market
Novartis has filed the PD-1 inhibitor tislelizumab, licensed from BeiGene, for second-line esophageal cancer with the FDA, the first submission outside China for the closely-watched therapy.
